<DOC>
	<DOCNO>NCT00667797</DOCNO>
	<brief_summary>An analysis cost outcomes associated hospitalization treatment Levalbuterol versus Racemic Albuterol subject Asthma COPD .</brief_summary>
	<brief_title>Costs &amp; Outcomes Hospitalization/Treatment With Levalbuterol &amp; Albuterol Asthma Chronic Obstructive Pulmonary Disease ( COPD ) Subjects</brief_title>
	<detailed_description>This randomize , open-label study evaluate clinical pharmacoeconomic outcome hospitalize patient asthma COPD admit due exacerbation disease require treatment beta2-adrenergic agonist . Approximately 430 patient randomize enrolled . Patients follow hospitalization . Once discharge , patient status assess via telephone interview 30 day discharge . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Male female subject must least great equal 18 year age time consent . Subjects must history asthma COPD least 6 month prior hospitalization . Subjects must hospitalize due exacerbation disease require treatment nebulized beta2adrenergic agonist . Subjects must oxygen saturation level great equal 90 % great equal 40 % face mask supplemental oxygen . Subjects likely Intensive Care Unit ( ICU ) Critical Care Unit ( CCU ) . Based upon history physical exam ED Clinic , subject know suspected cause pulmonary symptom asthma COPD , pneumonia , pulmonary embolism , cystic fibrosis , angioedema . Subjects CHF admit primary admission diagnosis COPD exclude . Female subject pregnant breast feeding . Subjects participate investigational drug study within 30 day study entry previously participate current trial . Subjects plan receive elective surgical procedure 30 day period hospital discharge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>COPD</keyword>
	<keyword>chronic emphysema</keyword>
	<keyword>chronic bronchitis</keyword>
</DOC>